Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Severe Asthma
97%
National Cohort Study
67%
Asthma
59%
Inhaled Corticosteroids
56%
Biologic Therapy
38%
Adult Asthma
29%
Childhood Asthma
21%
Clinical Remission
19%
Inhaled Corticosteroid Therapy
18%
All-cause Mortality
18%
Corticosteroid Exposure
17%
Remission
17%
Chronic Obstructive Pulmonary Disease
17%
Specialty Care
15%
Risk Factors
15%
Oral Corticosteroids
15%
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
15%
Anti-interleukin-5
13%
High Risk
13%
Corticosteroids
12%
Atopic Dermatitis
12%
Bronchiectasis
12%
Chronic Rhinosinusitis
12%
Asthma Burden
11%
Older Adults
11%
Clinical Response
11%
Corticosteroid Use
11%
Asthma Control
11%
Asthma Severity
11%
Asthma Patients
10%
Systemic Corticosteroids
10%
Hydroxychloroquine
10%
Statins
10%
Specialist Referral
10%
Asthma Specialist
10%
Azithromycin
10%
COVID-19
10%
Hospitalized Patients
10%
Antidepressant Use
10%
Dupilumab
10%
Medication Possession Ratio
9%
Uncontrolled Asthma
9%
Biological Treatment
9%
Hospitalization
8%
Comorbidity
8%
Fractional Exhaled Nitric Oxide (FeNO)
8%
Controller Medication
8%
Eosinophil Count
8%
High-dose Inhaled Corticosteroid
8%
Adult Patients
8%
Medicine and Dentistry
Asthma
100%
Severe Asthma
69%
Corticosteroid
69%
Biological Therapy
33%
Cohort Analysis
32%
Biological Product
17%
Health Care Cost
16%
Nasal Polyp
15%
Oral
14%
Specialist Care
14%
Chronic Rhinosinusitis
13%
Diseases
13%
Treatment Response
11%
Patient with Asthma
11%
Hydroxychloroquine
10%
Antidepressant
10%
Patient Referral
10%
Education
8%
Quality of Life
8%
COVID-19
7%
Drug Megadose
7%
Prevalence
6%
Bronchiectasis
6%
Morbidity
6%
Corticosteroid Therapy
6%
Prospective Cohort Study
6%
Socioeconomic Status
6%
Primary Health Care
6%
Attachment
6%
Respiratory Disease
5%
Disease Burden
5%
Topical Corticosteroid
5%
All Cause Mortality
5%
Interleukin 5
5%
Antidepressant Medication
5%
Infection
5%
Azithromycin
5%
Randomized Controlled Trial
5%
Work Capacity
5%
Dupilumab
5%
Tezepelumab
5%
Cost Benefit Analysis
5%
N [bis(1 Aziridinyl)phosphinyl] 4 Iodobenzamide
5%
Interleukin 5 Receptor
5%
Testosterone
5%
Fertility Outcome
5%
Adolescence
5%
Atopic Dermatitis
5%
Asthma Control Questionnaire
5%
